目的 探討杏貝止咳顆粒輔助治療老年慢性阻塞性肺疾病（COPD）穩(wěn)定期患者的臨床療效。方法 選取2019年12月—2021年12月南京市高淳人民醫(yī)院呼吸科門診就診的COPD穩(wěn)定期患者88例，按照隨機(jī)數(shù)字表法分為對(duì)照組和試驗(yàn)組，每組各44例。對(duì)照組患者使用常規(guī)藥物［布地奈德福莫特羅吸入粉霧劑（II）］聯(lián)合健康教育治療；試驗(yàn)組在對(duì)照組的基礎(chǔ)上加用杏貝止咳顆粒治療，兩組均治療6個(gè)月。分別于治療前及治療24周后測(cè)定兩組患者肺功能指標(biāo)［第1秒用力呼氣容積（FEV1）、第1秒用力呼氣容積占預(yù)計(jì)值百分比（FEV1%）、用力肺活量（FVC）］，分別于治療前后對(duì)兩組患者進(jìn)行焦慮自評(píng)量表（SAS）和抑郁自評(píng)量表（SDS）評(píng)分以及日常生活質(zhì)量（ADL）和COPD患者生活質(zhì)量（CAT）評(píng)分。觀察兩組患者治療期間不良反應(yīng)發(fā)生情況。結(jié)果 兩組研究對(duì)象的一般人口學(xué)資料（年齡、性別、婚姻狀況、文化程度、月平均收入等）比較，差異均無(wú)統(tǒng)計(jì)學(xué)意義（P＞0.05）；兩組研究對(duì)象的疾病相關(guān)資料（病程、合并疾病、吸氧、氧療、呼吸困難嚴(yán)重程度、注射疫苗等）比較，差異均無(wú)統(tǒng)計(jì)學(xué)意義（P＞0.05）。治療后兩組患者SAS和SDS評(píng)分均較本組治療前顯著降低（P＜0.05），且治療后試驗(yàn)組SAS和SDS評(píng)分顯著低于對(duì)照組（P＜0.05）。治療后兩組FEV1均較本組治療前有顯著升高（P＜0.05），F(xiàn)EV1%和FEV1/FVC均顯著升高（P＜0.05）；且治療后，與對(duì)照組比較試驗(yàn)組FEV1、FEV1%和FEV1/FVC均顯著升高（P＜0.05）；治療后兩組ADL評(píng)分均較本組治療前顯著升高（P＜0.05），CAT評(píng)分均較本組治療前顯著降低（P＜0.05）；且治療后，與對(duì)照組比較試驗(yàn)組ADL評(píng)分顯著升高（P＜0.05），CAT評(píng)分顯著降低（P＜0.05）。兩組治療期間均未出現(xiàn)明顯不良反應(yīng)。結(jié)論 杏貝止咳顆粒輔助治療COPD穩(wěn)定期患者能有效緩解患者焦慮抑郁狀態(tài)、改善肺功能，提高患者的生存質(zhì)量，值得臨床推廣。

Objective To explore the clinical efficacy of Xingbei Zhike Granule in the adjuvant treatment of elderly patients with chronic obstructive pulmonary disease (COPD) at stable stage.Methods A total of 88 patients with stable COPD from the respiratory department of Nanjing Gaochun People's Hospital from December 2019 to December 2021 were randomly selected, and divided into control group and experimental group according to random number method, with 44 patients in each group. Patients in the control group were treated with conventional drugs [Budesonide Formoterol Inhalation Powder Spray (II)] combined with health education. Patients in the experimental group were treated with Xingbei Zhike Granule on the basis of the control group, and both groups were treated for six months. The pulmonary function indexes (FEV1, FEV1%, FEV1/FVC) of the patients in the two groups were measured before and after treatment. The patients in the two groups were scored with the Self Rating Anxiety Scale (SAS) and the Self Rating Depression Scale (SDS) before and after treatment, as well as the quality of daily life (ADL) and the quality of life (CAT) of the patients with COPD. The adverse reactions of the two groups were observed during treatment.Results There was no significant difference in general demographic data (age, sex, marital status, education level, average monthly income, etc.) between the two groups (P > 0.05). There was no significant difference between the two groups in disease related data (course of disease, concomitant diseases, oxygen inhalation, oxygen therapy, severity of dyspnea, vaccine injection, etc.) (P > 0.05). After treatment, the SAS and SDS scores of the two groups were significantly lower than those before treatment (P <0.05), and the SAS and SDS scores of the experimental group were significantly lower than those of the control group (P <0.05). After treatment, FEV1 in both groups was significantly higher than that before treatment (P <0.05), FEV1% and FEV1/FVC increased significantly (P <0.05). After treatment, FEV1, FEV1% and FEV1/FVC in the experimental group were significantly higher than those in the control group (P <0.05). After treatment, ADL scores in both groups were significantly higher than those before treatment (P <0.05), and CAT scores were significantly lower than those before treatment (P <0.05). After treatment, compared with the control group, the ADL score in the experimental group was significantly higher (P <0.05), while the CAT score was significantly lower (P <0.05). There was no obvious adverse reaction in both groups during treatment.Conclusion Xingbei Zhike Granule can effectively relieve anxiety and depression, improve lung function, and improve the quality of life of patients with stable COPD, which is worthy of clinical promotion.

R974

南京市中醫(yī)藥青年人才培養(yǎng)計(jì)劃項(xiàng)目(ZYQ20065);江蘇省老年健康科研項(xiàng)目(LSD2022005)